Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Wednesday

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, July 31st. Analysts expect Syros Pharmaceuticals to post earnings of ($0.79) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative return on equity of 395.36% and a negative net margin of 1,656.34%. During the same period last year, the firm posted ($0.85) earnings per share. On average, analysts expect Syros Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syros Pharmaceuticals Stock Up 2.2 %

Shares of SYRS traded up $0.14 on Tuesday, hitting $6.61. The company’s stock had a trading volume of 64,453 shares, compared to its average volume of 161,658. The firm has a market capitalization of $176.69 million, a price-to-earnings ratio of -1.36 and a beta of 1.53. The firm’s fifty day moving average price is $5.54 and its 200-day moving average price is $5.96. The company has a quick ratio of 3.01, a current ratio of 3.01 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals has a fifty-two week low of $2.09 and a fifty-two week high of $8.17.

Insider Transactions at Syros Pharmaceuticals

In other news, Director Richard A. Young sold 34,837 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $5.12, for a total transaction of $178,365.44. Following the sale, the director now owns 8,000 shares in the company, valued at approximately $40,960. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 12.26% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. StockNews.com upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 15th. Piper Sandler restated an “overweight” rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Syros Pharmaceuticals in a research note on Wednesday, June 26th.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.